Unfortunately, depending on the threshold used to define AR-positivity, ~65–88% of TNBC patients are AR-negative and are thus classified as having quadruple-negative breast cancer or QNBC, and AR-targeted treatments are unlikely to significantly benefit this patient subgroup [9]. Here, AR is linked to breast carcinoma.